D. E. Shaw & Co. Inc. Cuts Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

D. E. Shaw & Co. Inc. trimmed its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 55.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 306,744 shares of the company's stock after selling 384,322 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.45% of Amylyx Pharmaceuticals worth $1,159,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company's stock worth $455,000 after purchasing an additional 83,048 shares in the last quarter. American Century Companies Inc. raised its holdings in Amylyx Pharmaceuticals by 181.8% during the fourth quarter. American Century Companies Inc. now owns 59,310 shares of the company's stock worth $224,000 after buying an additional 38,261 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Amylyx Pharmaceuticals in the fourth quarter valued at $205,000. Wellington Management Group LLP acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at about $793,000. Finally, Bank of America Corp DE grew its holdings in shares of Amylyx Pharmaceuticals by 165.9% during the fourth quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock valued at $9,171,000 after buying an additional 1,513,748 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.

Amylyx Pharmaceuticals Trading Up 2.3%

Shares of AMLX traded up $0.11 on Thursday, reaching $4.90. 550,620 shares of the company's stock traded hands, compared to its average volume of 1,213,777. The stock's 50 day simple moving average is $4.40 and its two-hundred day simple moving average is $4.16. The stock has a market cap of $436.79 million, a PE ratio of -1.28 and a beta of -0.60. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.03. Analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Mizuho raised their target price on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an "outperform" rating in a report on Wednesday, May 14th. Leerink Partners raised Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $4.00 to $10.00 in a research report on Wednesday, May 7th. Finally, HC Wainwright increased their price target on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $9.83.

Insiders Place Their Bets

In other news, Director Bernhardt G. Zeiher bought 10,000 shares of the stock in a transaction on Thursday, March 20th. The shares were purchased at an average cost of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $37,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Camille L. Bedrosian sold 12,425 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the transaction, the insider now owns 194,375 shares of the company's stock, valued at $674,481.25. The trade was a 6.01% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,811 shares of company stock valued at $155,494. Company insiders own 11.70% of the company's stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.